IMI at the Drug Information Association (DIA) Annual EuroMeeting
IMI reached out to the more than 3 000 attendees at the DIA (Drug Information Association) Annual EuroMeeting [1], held in Copenhagen, Denmark from 26 to 28 March.
At the exhibition
IMI’s exhibition stand attracted hundreds of curious visitors, eager to find out more about IMI’s work and how they can get involved in it. In addition, the many students who attended the event benefitted from advice from IMI’s Education & Training projects, who had their own stand at the exhibition.
In the sessions
IMI – does the European public-private partnership programme stimulate innovation?
Tuesday 27 March, 11:00-12:30 (session 0102)
Chaired by IMI Executive Director Michel Goldman, this session looked at IMI’s achievements to date and discussed the challenges and outlook for the future.
Peter Andersen, Senior Vice President, Corporate Affairs, Lundbeck A/S - The Industry Perspective [2] 
Ruxandra Draghia-Akli, Director Health, Research and Innovation DG, European Commission - The European Commission Perspective [3]
Marta Segerdahl, Medical Science Director,AstraZeneca - First Achievements of a consortium deciphering chronic pain [4]
Jan Geissler, Director, European Patients’ Academy on Therapeutic Innovation - EUPATI The Informed Patient as Stakeholder in Drug Development [5]
European Patients Academy on Therapeutic Innovation (EUPATI) – launch meeting
Tuesday 27 March, 14:00-15:30 (satellite session)
New IMI project EUPATI [6], which aims to boost public understanding about the drug development process, held its first public meeting during the DIA EuroMeeting.
Translational medicine – a global perspective
Tuesday 27 March, 16:00-17:30 (session 0604)
IMI Executive Director Michel Goldman chaired this session, which looked at the success of ongoing public-private partnerships at promoting drug development.
Sherri Hubby, Director, Quality Assurance, Premier Assurance - A Global Perspective from ethics, accreditation bodies and industry on conduct of clinical trials [7]
Michael Merz, Novartis Institutes for BioMedical Research - Translation of Safety Biomarkers in the Clinical Setting [8]
David Wholley, Director, The Biomarkers Consortium Foundation for the NIH - US Partnerships in Translational Medicine [9]
Taking the lead in drug development education in a global world
Wednesday 28 March, 14:00-15:30 (session 1407)
Fritz Bühler of the European Center of Pharmaceutical Medicine will present the work of PharmaTrain [10], one of IMI’s Education & Training projects.
Antimicrobial resistance and new antibiotics - how to avoid a lack of therapeutic options
Wednesday 28 March, 16:00-17:30 (session 0108)
This session, chaired by EFPIA Director General Richard Bergström, featured a discussion on IMI's future topic [11] on antimicrobial resistance.
About the DIA Annual EuroMeeting
The Drug Information Association [12] (DIA) is a non-profit, global association of approximately 18 000 members who are involved in the discovery, development, regulation, surveillance or marketing of pharmaceuticals or related products. The organisation’s Annual EuroMeeting [1] attracts well over 3 000 attendees from over 50 countries, including professionals from the biopharmaceutical industry, contract research and service organisations, academic research centres, regulatory agencies and health ministries as well as delegates from patient organisations. The 2012 edition of the DIA Annual EuroMeeting was held at Copenhagen’s Bella Center [13].
[14]